18F-FDG versus 18F-FDOPA PET in recurrent medulloblastoma: a case study and literature review

Medulloblastoma is a heterogeneous central nervous system tumor stratified into four molecular subgroups in the revised 2021 WHO classification. Although MRI remains essential for follow-up, distinguishing true recurrence from treatment-related changes can be challenging. PET imaging may provide additional value in this context; however, evidence in medulloblastoma is limited to small series and case reports, with most available PET data originating from glioma studies. Here, we report a medulloblastoma patient experiencing two recurrences assessed sequentially with 18F-FDOPA and 18F-FDG PET imaging. This case highlights considerations in PET tracer selection, aiming to support clinical decision-making and enhance diagnostic accuracy for physicians managing recurrent medulloblastoma.